Para poder acceder a la web de la GT debes tener el código de registro de la 8a edición de la Guía. No son válidos los códigos de ediciones anteriores. Si no has registrado tu código, debes hacerlo aquí.

Registrarse

¿Has olvidado la contraseña?

Para cualquier consulta o incidencia, puedes contactarnos a través del correo guiaterapeutica@semfyc.es

Problemas cardíacos, vasculares y hematológicos

  • Abilleira S, Alonso P, Álvarez J, Armario P, Arrieta E, Borrás FX, et al. Guía de Práctica Clínica sobre la Prevención Primaria y Secundaria del Ictus (2009). Centro Cochrane Iberoamericano. [acceso el 19 Abr 2011]. Disponible en: http://www.guiasalud.es/GPC/GPC_442_Prevencion_Ictus.pdf
  • Aguado O, Aleix C, Álvarez J, Cacho A, Egocheaga MI, Gracia J, et al. Guía de Práctica Clínica para el Manejo de Pacientes con Ictus en Atención Primaria (2009). Unidad de Evaluación de Tecnologías Sanitarias (UETS) de la Agencia Laín Entralgo. [Acceso el 19 Abr 2011]. Disponible en: http://www.guiasalud.es/GPC/GPC_466_Ictus_AP_Lain_Entr_compl.pdf
  • Brotons C, Alemán JJ, Banegas JR, Fondón C, Lobos-Bejarano JM, Martín E, et al. Recomendaciones preventivas cardiovasculares. Actualización PAPPS 2018. Aten Primaria. 2018; 50 (Supl 1):4-28
  • Brugts JJ, van Vark L, Akkerhuis M, Bertrand M, Fox K, Mourad JJ, et al. Impact of renin–angiotensin system inhibitors on mortality and major cardiovascular endpoints in hypertension: A number-needed-to-treat analysis. Int J Cardiol. 2015;181:425-9.
  • Byberg L, Melhus H, Gedeborg R, Sundström J, Ahlbom A, Zethelius B, et al. Total mortality after changes in leisure time physical activity in 50 year old men: 35 year follow-up of population based cohort. BMJ. 2009 Mar 5;338:b688.
  • Fokkenrood HJ, Bendermacher BL, Lauret GJ, Willigendael EM, Prins MH, Teijink JA. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev. 2013 Aug 23;8:CD005263.
  • Ginsberg HN, Elam MB, Lovato LC, Crouse JR 3rd, Leiter LA, Linz P, et al., ACCORD Study Group. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1563-74. Epub 2010 Mar 14. Erratum in: N Engl J Med. 2010 May 6;362(18):1748.
  • Ibáñez B, James S, Agewall S, Antunes MJ, Bucciarelli-Ducci C,Bueno H et al. Guia ESC 2017 sobre el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento del infarto agudo de miocardio en pacientes con elevación del segmento ST. Rev Esp Cardiol. 2017;70(12):1082.e1-e61.
  • Iglesias JM, Gómez MA, González ML, García L, Mediavilla JJ, Garzón A, et al. Valoración y tratamiento del riesgo cardiovascular (2008). Sociedad Castellano Leonesa de Medicina Familiar y Comunitaria, Sociedad Española de Médicos de Atención Primaria, Sociedad Española de Médicos Generales y de Familia, Asociación de Enfermería Comunitaria, Sociedad Española de Enfermería Familiar y Comunitaria, Sociedad Castellano-Leonesa de Endocrinología y Nutrición, Sociedad Castellano-Leonesa de Cardiología. [acceso el 19 Abr 2011]. Disponible en: http://www.guiasalud.es/GPC/GPC_418.pdf
  • Kausik KR, Seshasai SRK, Erqou S, Sever P, Jukema JW, Ford I, et al. Statins and All-Cause Mortality in High-Risk Primary Prevention: A Meta-analysis of 11 Randomized Controlled Trials Involving 65 229 Participants. Arch Intern Med. 2010;170(12):1024-31.
  • María Grau M, Marrugat J. Funciones de riesgo en la prevención primaria de las enfermedades cardiovasculares. Rev Esp Cardiol. 2008;61(4):404-16.
  • Pignone M, Alberts MJ, Colwell JA, Cushman M, Inzucchi SE, Mukherjee D, et al; American Diabetes Association; American Heart Association; American College of Cardiology Foundation. Aspirin for primary prevention of cardiovascular events in people with diabetes: a position statement of the American Diabetes Association, a scientific statement of the American Heart Association, and an expert consensus document of theAmerican College of Cardiology Foundation. Diabetes Care. 2010 Jun;33(6):1395-402.
  • Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL et alGuia ESC 2016 sobre prevención de la enfermedad cardiovascular en la práctica clínica Sexto Grupo de Trabajo Conjunto de la Sociedad Europea de Cardiologia y otras Sociedades sobre Prevencion de Enfermedad Cardiovascular en la Practica Clínica (constituido por representantes de 10 sociedades y expertos invitados). Rev Esp Cardiol. 2016;69(10):939.e1-e87
  • Raposeiras S, Agra RM y González-Juanatey JR. Síndrome coronario agudo con y sin elevación del segmento ST: ¿cómo darles igualdad de oportunidades?. Rev Esp Cardiol Supl. 2013;13(B):24-28
  • Risk estimation and the prevention of cardiovascular disease. Nº 97 Guideline. Scottish Intercollegiate Guideline Network (SIGN). [acceso el 18 Abr 2011]. Disponible en: http://www.sign.ac.uk/pdf/sign97.pdf
  • Ros Pérez P, Manso Pérez A. Urgencias endocrinológicas en Pediatría. Protoc diagn ter pediatr. 2019;1:307-28.
  • San Vicente R, Pérez I, Ibarra J, Berraondo I, Uribe F, Urraca J, et al. Guía de práctica clínica sobre el manejo de los lípidos como factor de riesgo cardiovascular (2008). Osakidetza y Departamento de Sanidad, Administración de la CCAA del País Vasco. [Acceso el 19 Abril 2011]. Disponible en: http://www.guiasalud.es/GPC/GPC_433_Lipidos_compl_cast.pdf
  • Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al. AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. Circulation. 2006;113:2363-72.
  • Suárez C, Álvarez-Salab L, Mostazac J, Asenjod C, Grupo Multidisciplinario para el Estudio del Riesgo Cardiovascular. Cálculo del riesgo cardiovascular. Med Clin (Barc). 2007;129(14):534-41.
  • Taylor F, Ward K, Moore THM, Burke M, Davey Smith G, Casas JP, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database of Systematic Reviews 2011, Issue 1. Art. No.: CD004816.

Anemia ferropénica

  • Alleyne M, Horne MK, Miller JL. Individualized treatment for iron-deficiency anemia in adults. Am J Med. 2008 Nov;121(11):943-8.
  • Avni T, Bieber A, Grossman A, Green H, Leibovici L, Gafter-Gvili A. The safety of intravenous iron preparations: systematic review and meta-analysis. Mayo Clin Proc. 2015 Jan;90(1):12-23.
  • Camaschella C. Iron-deficiency anemia. N Engl J Med. 2015 May 7;372(19):1832-43.
  • García Erce JA, Altés A, López Rubio M, Remacha AF; en representación del Grupo Español de Eritropatología de la Sociedad Española de Hematología y Hemoterapia. Manejo del déficit de hierro en distintas situaciones clínicas y papel del hierro intravenoso: recomendaciones del Grupo Español de Eritropatología de la SEHH. Rev Clin Esp. 2020 Jan-Feb;220(1):31-42.

  • Lindblad AJ, Cotton C, Allan GM. Iron deficiency anemia in the elderly. Can Fam Physician. 2015 Feb;61(2):159.
  • Means RT. Iron deficiency anemia. Hematology. 2013 Sep;18(5):305-6.
  • Short MW, Domagalski JE. Iron deficiency anemia: evaluation and management. Am Fam Physician. 2013 Jan 15;87(2):98-104.
  • Goddard AF, James MW, McIntyre AS, Scott BB, on behalf of the British Society of Gastroenterology. Guidelines for the management of iron deficiency anaemia, 2005. [Acceso el 12 Jun 2008]. Disponible en: http://www.bsg.org.uk/pdf_word_docs/iron_def.pdf
  • Killip S, Bennett JM, Chambers MD. Iron deficiency anemia. Am Fam Physician. 2007;75(5):671-8.

Anemia megaloblástica. Anemias por déficit de Vit B12 o folatos

  • Agrela Cardona M, Ordoñez Ruiz MJ, Cerezo Sánchez P. Atención al embarazo normal. AMF. 2016;12(6):316-26.
  • Butler CC, Vidal-Alaball J, Cannings-John R, McCaddon A, Hood K, Papaioannou A, et al. Oral vitamin B12 versus intramuscular vitamin B12 for vitamin B12 deficiency: a systematic review of randomized controlled trials. Fam Pract. 2006 Jun;23(3):279-85.
  • Goetzl LM. Folic acid supplementation in pregnancy. UpToDate 2019.
  • Guía de práctica clínica de atención en el embarazo y puerperio. Ministerio de Sanidad, Servicios Sociales e Igualdad. Agencia de Evaluación de Tecnologías Sanitarias de Andalucía; 2014.
  • Hesdorffer CS, Longo DL. Drug-Induced Megaloblastic Anemia. N Engl J Med. 2015;373(17):1649-58.
  • Hunt A, Harrington D, Robinson S. Vitamin B12 deficiency. BMJ. 2014 Sep 4;349:g5226.
  • Langan RC, Zawistoski KJ. Update on vitamin B12 deficiency. Am Fam Physician. 2011 Jun 15;83(12):1425-30.
  • Vidal-Alaball J, Butler CC, Cannings-John R, Goringe A, Hood K, McCaddon A, et al. Administración oral versus intramuscular de vitamina B12 para el tratamiento de la deficiencia de vitamina B12 (Revisión Cochrane traducida). Biblioteca Cochrane Plus, 2008 Número 4.
  • Wald NJ. Folic Acid and the Prevention of Neural-Tube Defects. N Engl J Med. 2004;350:101-2.

Anticoagulación oral

  • Aguilar MI, Hart R, Pearce LA. Oral Anticoagulants Versus Antiplatelet Therapy for Preventing Stroke in Patients With Non-Valvular Atrial Fibrillation and No History of Stroke or Transient Ischemic Attacks. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006186.
  • Algra A, De Schryver EL, van Gijn J, Kappelle LJ, Koudstaal PJ. Oral anticoagulants versus antiplatelet therapy for preventing further vascular events after transient ischaemic attack or minor stroke of presumed arterial origin. Cochrane Database Syst Rev. 2006 Jul 19;(3):CD001342.
  • Cairns JA, Connolly S, McMurtry S, Stephenson M, Talajic M; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter. Can J Cardiol. 2011 Jan-Feb;27(1):74-90.
  • Carrasco Expósito M. Tratamiento con anticoagulantes orales: inicio, ajuste y precauciones en su utilización. Av Diabetol. 2010;26:17-20.
  • Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anticoagulant therapy alone among patients at risk for cardiovascular disease: a meta-analysis of randomized trials. Arch Intern Med. 2007 Jan 22;167(2):117-24.
  • Eikelboom JW, Weitz JI. New anticoagulants. Circulation. 2010 Apr 6;121(13):1523-32.
  • Estes NAM 3rd, Halperin JL, Calkins H, Ezekowitz MD, Gitman P, Go AS, et al. ACC/AHA/Physician Consortium 2008 clinical performance measures for adults with nonvalvular atrial fibrillation or atrial flutter: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and the Physician Consortium for Performance Improvement (Writing Committee to Develop Performance Measures for Atrial Fibrillation). Circulation. 2008;117:1101-20.
  • García DA, Regan S, Henault LE, Upadhyay A, Baker J, Othman M, et al. Risk of Thromboembolism With Short-term Interruption of Warfarin Therapy. Arch Intern Med. 2008;168(1):63-9.
  • Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007 Jun 19;146(12):857-67.
  • Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD005158.
  • Lip GY, Boos CJ. Antithrombotic treatment in atrial fibrillation. Postgrad Med J. 2008 May;84(991):252-8.
  • Mant J, Hobbs R, Fletcher K, Roalfe A, Fitzmaurice D, YH Lip G, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (The Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
  • Proceso Asistencial Integrado para la atención de pacientes con tratamiento anticoagulante. Junta de Castilla y León. Consejería de Sanidad. Gerencia Regional de Salud. Dirección General de Asistencia Sanitaria, Dirección Técnica de Asistencia Sanitaria, Servicio de Organizacion de Centros Asistenciales. Edición: Junio 2019. Disponible en: https://www.saludcastillayleon.es/profesionales/es/procesos-asistenciales/procesos-asistenciales-gerencia-regional-salud/anticoagulacion
  • Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. WITHDRAWN: Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001938.
  • Wysokinski WE, McBane RD, Daniels PR, Litin SC, Hodge DO, Dowling NF, et al. Periprocedural anticoagulation management of patients with nonvalvular atrial fibrillation. Mayo Clin Proc. 2008 Jun;83(6):639-45.

Bradicardia sintomática

  • Deal N. Evaluation and management of bradydysrhythmias in the emergency department. Emerg Med Pract. 2013 Sep;15(9):1-15.
  • Gargallo García E, Calderón Moreno M, Castuera Gil AI, Fernández Cardona M. Protocolo terapéutico de las arritmias en Urgencias. Medicine. 2015;11(87): 5218-22.
  • Vogler J, Breithardt G, Eckardt L. Bradiarritmias y bloqueos de la conducción. Rev Esp Cardiol. 2012;65(7):656-67.

Cardiopatía isquémica. Sospecha de síndrome coronario agudo

  • Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernández-Avilés F, grupo de trabajo para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST de la Sociedad Europea de Cardiología. Guía de Práctica Clínica para el diagnóstico y tratamiento del síndrome coronario agudo sin elevación del segmento ST. Rev Esp Cardiol. 2007;60(10):1070.e1-e80.
  • Código Infarto en Catalunya. [Acceso Octubre 2015]. Disponible en: http://canalsalut.gencat.cat/ca/home_professionals/temes_de_salut/codi_iam/
  • Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, et al. ESC Scientific Document Group. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020 Aug 29: ehaa575. doi: 10.1093/eurheartj/ehaa575. Epub ahead of print.

  • Early management of unstable angina and NSTEMI. NICE National Institute for Health and Care Excellence. Pathway last updated: 21 July 2015. [Acceso Octubre 2015]. Disponible en: http://pathways.nice.org.uk/pathways/acute-coronary-syndromes
  • Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA /ACC /AACVPR /AAPA /ABC /ACPM /ADA /AGS /APhA /ASPC /NLA /PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-209.
  • Hamm CW, Bassand JP, Agewall S, Bax J, Boersma E, Bueno H et al. Guia de práctica clinica de la ESC para el manejo del sindrome coronario agudo en pacientes sin elevación persistente del segmento ST. Rev Esp Cardiol. 2012; 65(2):173.e1-e55.
  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal 2020; 41: 407-477.

  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. Guía ESC 2019 sobre el diagnóstico y tratamiento de los síndromes coronarios crónicos. Rev Esp Cardiol. 2020;73(6):495.e1–495.e61. Disponible en: https://www.revespcardiol.org/es-pdf-S0300893220301007.
  • Kushner FG, Hand M, Smith SC Jr, King SB 3rd, Anderson JL, Antman EM, et al. 2009 Focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;120:2271-306.
  • Mehta SR, Bassand JP, Chrolavicius S, Diaz R, Eikelboom JW, Fox KA, et al, Current-oasis. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med. 2010 Sep 2;363(10):930-42. Erratum in: N Engl J Med. 2010 Oct 14;363(16):1585.
  • Myocardial infarction with STsegment elevation. The acute management of myocardial infarction with ST-segment elevation. Issued: July 2013. NICE clinical guideline 167. [Acceso Octubre 2015]. Disponible en: http://www.nice.org.uk/guidance/cg167
  • Programa de asistencia al sindrome coronario agudo con elevacion del ST en la comunidad aragonesa (triamar 2) 26 de enero de 2015. Codigo infarto en Aragón. [Acceso Octubre 2015]. Disponible en: http://www.aragon.es/estaticos/GobiernoAragon/Departamentos/SanidadBienestarSocialFamilia/Sanidad/Profesionales/06_Planes_Estrategia/1programa.pdf
  • Savonittoa S, Moricib N, De Servic S. El tratamiento de síndromes coronarios agudos de ancianos y pacientes con comorbilidades. Rev Esp Cardiol. 2014; 67(7):564-73.
  • Steg G, James SK, Atar D, Badano LP, Lundqvist CB, Borger MA, et al. Guia de práctica clinica de la ESC para el manejo del infarto agudo de miocardio en pacientes con elevacion del segmento ST. Rev Esp Cardiol. 2013;66(1):53.e1-e46.
  • Unstable Angina and NSTEMI: the early management of unstable angina and non-ST-segment-elevation myocardial infarction NICE Clinical guideline 94 (2010). [Consultado el 20 Abr 2011]. Disponible en: http://guidance.nice.org.uk/CG94
  • Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60.
  • Van de Werf F, Bax J, Betriu A, Blomstrom-Lundqvist C, Crea F, Falk V, et al. Guías de Práctica Clínica de la Sociedad Europea de Cardiología (ESC). Manejo del infarto agudo de miocardio en pacientes con elevación persistente del segmento ST. Grupo de Trabajo de la ESC sobre el manejo del infarto agudo de miocardio con elevación del segmento ST (IAMCEST). Rev Esp Cardiol. 2009;62(3):e1-e47.
  • Wright RS, Anderson JL, Adams CD, Bridges CR, Casey DE Jr, Ettinger SM, et al. 2011ACCF/AHA focused update of the guidelines for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2011;57 (18):xxx-xxx. [Acceso 20 de abril de 2011]. Disponible en: http://content.onlinejacc.org/cgi/reprint/j.jacc.2011.02.009v1.pdf

Cardiopatía isquémica estable. Angina estable o postinfarto

  • Bangalore S, Qin J, Sloan S, Murphy SA, Cannon CP; PROVE IT-TIMI 22 TrialInvestigators. What is the optimal blood pressure in patients after acute coronary syndromes?: Relationship of blood pressure and cardiovascu lar events in the PRavastatin OR atorVastatin Evaluation and Infection Therapy-Thro mbolysis In Myocardial Infarction (PROVE IT-TIMI) 22 trial. Circulation. 2010 Nov 23;122(21):2142-51.
  • Fluixá C, Ajenjo A, Bonet A, Botija MP, Fornos A, Franch M, et al.. Prevención secundaria de la cardiopatía isquémica en Atención Primaria (2010).Grupo de Trabajo de Patología Cardiovascular de la Sociedad Valenciana de Medicina Familia r y Comunitaria (SVMFYC). [Acceso el 19 Abr 2011]. Disponible en: http://www.guiasalud.es/GPC/GPC_388_IAM_Valencia_2010.pdf
  • Fox K, Alonso MA, Ardissino D, Buszman P, Camici PG, Crea F, et al., Grupo de Trabajo de la Sociedad Europea de Cardiología sobre el Manejo de la Angina Estable. Guía sobre el manejo de la angina estable. Versión resumida. Rev Esp Cardiol. 2006;59(9):919-70.
  • Fraker TD Jr, Fihn SD. 2007 chronic angina focused update of the ACC/AHA 2002 guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Writing Group to Develop the Focused Update of the 2002 guidelines for the management of patients with chronic stable angina. Circulation. 2007;116:2762-72.
  • Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, Pipe A, et al. Impact of smoking on cardiovascular events in patients with coronary disease receiving contemporary medical therapy (from the Treating to New Targets [TNT] and the Incremental Decrease in End Points Through Aggressive Lipid Lowering[IDEAL] trials). Am J Cardiol. 2011 Jan 15;107(2):145-50.
  • Gibson CM, Pride YB, Hochberg CP, Sloan S, Sabatine MS, Cannon CP; TIMI Study Group. Effect of intensive statin therapy on clinical outcomes among patientsundergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol. 2009 Dec 8;54(24):2290-5.
  • González AI. Seguimiento del paciente isquémico estable. AMF. 2007;3(6):344-9.
  • Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA /ACC /AACVPR /AAPA /ABC /ACPM /ADA /AGS /APhA /ASPC /NLA /PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2019;73(24):3168-209.
  • Grupo de Trabajo de la SEC para la guia de la ESC 2013 sobre diagnóstico y tratamiento de la cardiopatía isquemica estable, revisores expertos para la guia de la ESC 2 013 sobre diagnostico y tratamiento de la cardiopatia isquemica estable y Comite de Guias de la SEC. Comentarios a la guia de practica clinica de la ESC 2013 sobre diagnostico y tratamiento de la cardiopatia isquemica estable. Rev Esp Cardiol. 2014; 67(2):80-6.
  • Interaction between clopidogrel and proton-pump inhibitors. Public statement. European medicines agency (EMA). EMA/174948/2010. [17 Mar 2010].
  • Johnson DA, Chilton R, Liker HR. Proton-pump inhibitors in patients requiring antiplatelet therapy: new FDA labeling. Postgrad Med. 2014 May;126 (3):239-45.
  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. 2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes: The Task Force for the diagnosis and management of chronic coronary syndromes of the European Society of Cardiology (ESC). European Heart Journal 2020; 41: 407-77.

  • Knuuti J, Wijns W, Saraste A, Capodanno D, Barbato E, Funck-Brentano C et al. Guía ESC 2019 sobre el diagnóstico y tratamiento de los síndromes coronarios crónicos. Rev Esp Cardiol. 2020;73(6):495.e1–495.e61. Disponible en: https://www.revespcardiol.org/es-pdf-S0300893220301007

  • López de la Iglesia J, Vega AB, Díez F. Cardiopatía isquémica. AMF. 2006;2(6):309-19.
  • Management of stable coronary disease. N Engl J Med. 2007;357:1762-6.
  • Managing stable angina. NICE National Institute for Health and Care Excellence. Pathway last updated: 21 July 2015. [Acceso Octubre 2011]. Disponible en: http://pathways.nice.org.uk/pathways/stable-angina
  • Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, et al. Guia de Practica Clinica de la ESC 2013 sobre diagnostico y tratamiento de la cardiopatia isquemica estable. Rev Esp Cardiol. 2014;67(2):135.e1-e81.
  • Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation andInfection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol. 2009 Dec 15;54(25):2358-62.
  • National Institute for Health and Clinical Excellence (NICE). Secondary prevention in primary and secondary care for patients following a myocardial infarction 2007. [Acceso 19 Abr 2011]. Disponible en: http://www.nice.org.uk/nicemedia/pdf/CG48NICEGuidance.pdf
  • O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, et al. Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials. Lancet. 2009;374:989-97.
  • Park SJ, Park DW, Kim YH, Kang SJ, Lee SW, Lee CW, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362(15):1374-82.
  • Quiles J, Miralles-Vicedo B. Estrategias de prevención secundaria del síndrome coronario agudo. Rev Esp Cardiol. 2014;67(10):844-8.
  • Rodés-Cabau J, Tardif JC, Cossette M, Bertrand OF, Ibrahim R, Larose E, et al. Acute effects of statin therapy on coronary atherosclerosis following an acute coronary syndrome. Am J Cardiol. 2009 Sep 15;104(6):750-7.
  • Smith SC, Allen J, Blair SN, Bonow RO, Brass LM, Fonarow GC, et al., AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update. J Am Coll Cardiol. 2006 [acceso el 29 May 2008];47:2130-9. Disponible en: http://content.onlinejacc.org/cgi/reprint/47/10/2130
  • Valgimigli M, Bueno H, Byrne RA, Collet JP, Costa F, Jeppsson A, et al; ESC Scientific Document Group; ESC Committee for Practice Guidelines (CPG); ESC National Cardiac Societies. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2018;39(3):213-60.
  • Wijns W, Kolh Ph, Danchin N, Di Mario C, Falk V, Folliguet T, et al. Guía de práctica clínica sobre revascularización miocárdica. Grupo de Trabajo de Revascularización Miocárdica de la Sociedad Europea de Cardiología (ESC) y de la Asociación Europea de Cirugía Cardiotorácica (EACTS). Rev Esp Cardiol. 2010;63(12):1485.e1-e76.

Claudicación intermitente. Arteriopatía periférica

  • Agencia española de medicamentos y productos sanitarios (AEMPS). Cilostazol: calificado como medicamento de diagnóstico hospitalario. Medicamentos uso humano seguridad. MUH (FV) 14/2013.
  • Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, et al. Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA. 2013;309(5):453-60.
  • Burns P, Gough St, Bradbury AW. Management of peripheral arterial disease in primary care. BMJ. 2003;326:584-8.
  • Cassar K. Peripheral arterial disease. Clin Evid (On-line). 2011 Jan 11;2011.pii: 0211
  • Hirsch AT, Haskal ZJ, Hertzer NR. Peripheral Arterial Disease: ACC/AHA 2005 Guidelines for the Management of Patients With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and Abdominal Aortic): A Collaborative Report From the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease). J Am Coll Cardiol. 2006;47:1239-312.
  • Kamal A, Naqvi I, Husain M, Khealani B. Cilostazol versus aspirina para la prevención secundaria de los eventos vasculares después del accidente cerebrovascular de origen arterial. Cochrane Database of Systematic Reviews 2011 Issue 1. Art. No.: CD008076. DOI: 10.1002/14651858.CD008076
  • McDermott MM, Liu K, Guralnik JM, Criqui MH, Spring B, Tian L, et al. Home-based walking exerc ise intervention in peripheral artery disease: a randomized clinical trial. JAMA. 2013;310(1):57-65.
  • Robless P, Mikhailidis DP, Stansby GP. Cilostazol para pacientes con enfermedad arterial periférica (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, 2008 Número 4. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2008 Issue 3. Chichester, UK: John Wiley & Sons, Ltd.).
  • Ruiz-Canela M, Estruch R, Corella D, Salas-Salvadó J, Martínez-González MA. Association of Mediterranean diet with peripheral artery disease: the PREDIMED randomized trial. JAMA. 2014;311(4):415-7.
  • Serrano FJ, Martín A. Enfermedad arterial periférica: aspectos fisiopatológicos, clínicos y terapéuticos. Rev Esp Cardiol. 2007;60(9):969-82.
  • Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, Collet J-Ph, et al. Guía de práctica clínica de la ESC sobre diagnóstico y tratamiento de las enfermedades arteriales periféricas. Rev Esp Cardiol. 2012;65(2):172.e1-e57.
  • Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev. 2008;8(4):CD000990.

Enfermedad tromboembólica

  • Akl EA, Barba M, Rohilla S, Terrenato I, Sperati F, Muti P, et al. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer. Cochrane Database Syst Rev 2008 Apr 16;(2):CD006650.
  • Bartolomé R, Bartolomé FJ. Estudio básico ante una trombosis venosa profunda. FMC 2018;25(7):418-421.
  • Boehler K, Kittler H, Stolkovich S, Tzaneva S. Therapeutic effect of compression stockings versus no compression on isolated superficial vein thrombosis of the legs: a randomized clinical trial. EurJ Vasc Endovasc Surg. 2014;48: 465-71.
  • Caprini JA. Risk assessment as a guide for the prevention of the many faces of venous thromboembolism. Am J Surg. 2010 Jan;199(1 Suppl):S3-10.
  • Di Nisio M, Wichers IM, Middeldorp S. Treatment for superficial thrombophlebitis of the leg. Cochrane Database Syst Rev. 2018;2(2):CD004982. Disponible en: https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004982.pub6/full/es
  • Douketis JD. Trombosis venosa profunda. Manual MSD. Julio 2016. Disponible en: http://www.msdmanuals.com/eses/professional/trastornos-cardiovasculares/enfermedades-de-las-venasperif%C3%A9ricas/trombosis-venosa-profunda-tvp [Acceso 1/09/2019]
  • Duffett L, Kearon C, Rodger M, Carrier M. Treatment of Superficial Vein Thrombosis: A Systematic Review and Meta-Analysis. Thromb Haemost. 2019;119(3):479-89.
  • Fisher WD, Turpie AG. Outpatient thromboprophylaxis after hip or knee surgery: discrepancies and concerns. CMAJ 2008 Jun 3;178(12):1571-2.
  • Hyers TM, Spyropoulos AC; INNOVATE Investigators. Community-based treatment of venous thromboembolism with a low-molecular-weight heparin and warfarin. J Thromb Thrombolysis. 2007 Dec;24(3):225-32.
  • Jiménez S, Ruiz P, Peiró JF, Robledo C, Rial R, Moñux G et al. Respuestas en trombosis venosa superficial. De la bibliografía a la práctica. Barcelona: Saned 2020. Disponible en: http://www.capitulodeflebologia.org/wp-content/uploads/2020/11/2020-RESPUESTAS-EN-TROMBOSIS-VENOSA-SUPERFICIAL.pdf
  • Lip GYH, Hull RD. Overview of the treatment of lower extremity Deep vein thrombosis (DVT) [Internet]. Up To Date. Septiembre 2018. [Consulta el 1 de septiembre de 2019]. Disponible en: http://uptodateonline.com
  • Medrano Ortega FJ, Navarro Puerto A, Vidal Serrano S, Alonso Ortiz del Río C, Gutiérrez Tous R, Marín León I y cols. Guía PRETEMED- 2007 sobre prevención de enfermedad tromboembólica venosa en patología médica. Córdoba: SADEMI; 2007. [Acceso el 19 Abr 2011]. Disponible en: http://www.guiasalud.es/GPC/GPC_18_PRETEMED_2007.pdf
  • Otero R, Grau E, Jiménez D, Uresandi F, López JL, Calderón E y col. Profilaxis de la enfermedad tromboembólica venosa. Arch bronconeumol. 2008;44(3):160-9.
  • Rodríguez A, Vallano A. Profilaxis de la tromboembolia venosa en pacientes con procesos médicos agudos. Med Clin (Barc). 2006;126(19):754-6.
  • Schulman S. Current strategies in prophylaxis and treatment of venous thromboembolism. Ann Med. 2008;40(5):352-9.
  • Scovell S. Phlebitis and thrombosis of the superficial lower extremity veins. [Internet]. Update. [last updated: Feb 18, 2021].
  • Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, et al. Management of Venous Thromboembolism: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Fam Med 2007;5:74-80.
  • Spyropoulos AC, Mahan C. Venous thromboembolism prophylaxis in the medical patient: controversies and perspectives. Am J Med. 2009 Dec;122(12):1077-84.
  • Stone J, Hangge P, Albadawi H, Wallace A, Shamoun F, Knuttien MG, et al. Deep vein thrombosis: pathogenesis, diagnosis, and medical management. Cardiovasc Diagn Ther 2017;7(Suppl 3):S276-S284.
  • Venous thromboembolism in over 16s: reducing the risk of hospital-adquired deep vein thrombosis or pulmonary embolism. NICE clinical guideline 89 (2018) [Last updated: 13 August 2019]. [Acceso el 1 Sep 2021]. Disponible en: https://www.nice.org.uk/guidance/ng89
  • Villa R, Veiras O. Trombosis venosa profunda. AMF 2009;5(1):11-20 Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin inthe treatment of acute venous thromboembolism. N Engl J Med. 2009 Dec 10;361(24):2342-52

Extrasistolia

  • Andre G. Treating patients with ventricular ectopic beats. Heart. 2006;92:1707-12.
  • Jadhav A, Ingole A, Chockalingam A. Ventricular ectopic beats: an overview of management considerations. Am J Med Sci. 2012 Feb;343(2):150-4.
  • Jouven X, Zureik M, Desnos M, Courbon D, Ducimetiere P. Long-term outcome in asymptomatic men with exercise induced premature ventricular depolarizations. N Engl JMed. 2000;343:826-33.
  • Svendsen JH, Goette A, Dobreanu D, Marinskis G, Mabo P, Blomström-Lundqvist C, Scientific Initiative Committee, European Heart Rhythm Association. Outpatient evaluation and management of patients with ventricular premature beats or non-sustained ventricular tachycardia. Europace. 2012 Feb;14(2):294-6.
  • Voskoboinik A et al. Predictors of Adverse Outcome in Patients with Frequent Premature Ventricular Complexes: The ABC-VT Risk Score. Heart Rhythm 2020.

  • Winkens RA, Höppener PF, Kragten JA, Verburg MP, Crebolder HF. Are premature ventricular contractions always harmless? Eur J Gen Pract. 2014 Jun;20(2):134-8.

Fenómeno de Raynaud

  • Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, et al. Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 2006;166(2):231-3.
  • García-Carrasco M, Jiménez-Hernández M, Escárcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R, et al. Treatment of Raynaud's phenomenon. Autoimmun Rev. 2008 Oct;8(1):62-8.
  • Pope JE. Raynaud's phenomenon (primary). Clin Evid 2005;(13):1546-54.
  • Pope JE. The diagnosis and treatment of Raynaud's phenomenon: a practical approach. Drugs. 2007;67(4):517-25.
  • Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud's phenomenon: a meta-analysis. Rheumatology (Oxford) 2005;44(2):145-50.
  • Tolosa Vilella C, Simeón Aznar CP, Gabarró Julià L. Fenómeno de Raynaud. Med Clin (Barc). 2009 May 16;132(18):712-8.
  • Vinjar B, Stewart M. Oral vasodilators for primary Raynaud's phenomenon. Cochrane Database Syst Rev 2008 Apr 16;(2):CD006687.

Fibrilación auricular

  • Aguilar MI, Hart R, Pearce LA. Oral anticoagulants versus antiplatelet therapy for preventing stroke in patients with non-valvular atrial fibrillation and no history of stroke or transient ischemic attacks. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD006186.
  • Alegret JM, Viñolas X, Grande A, Castellanos E, Asso A, Tercedor L, et al. Utilidad en la práctica clínica del tratamiento antiarrítmico tras cardioversión eléctrica en pacientes sin cardiopatía estructural. Rev Esp Cardiol. 2008;61:1274-9.
  • Arcelus JI, Cairols M, Granero X, Jiménez D, Llau JV, Monreal M, Vicente V. Nuevos anticoagulantes orales:una visión multidisciplinaria. MedClin (Barc). 2009;133(13):508-12.
  • Batcher EL, Tang XC, Singh BN, Singh SN, Reda DJ, Hershman JM; SAFE-T Investigators. Thyroid function abnormalities during amiodarone therapy for persistent atrial fibrillation. Am J Med. 2007 Oct;120(10):880-5.
  • Camm AJ, Kirchhof P, Lip G, Schotten U, Savelieva I, Ernst S, et al. Grupo de Trabajo para el Manejo de la Fibrilación Auricular de la Sociedad Europea de Cardiología (ESC).Guías de práctica clínica para el manejo de la fibrilación auricular. Rev Esp Cardiol. 2010;63:1483.e1-e83.
  • Collaborative Group of the Spanish Society of Clinical Pharmacology. Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic. Eur J Clin Pharmacol. 1991;40:543-6.
  • Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51. Epub 2009 Aug 30. Erratum in: N Engl J Med. 2010 Nov 4;363(19):1877.
  • Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, Chrolavicius S, et al., ACTIVE Writing Group of the ACTIVE Investigators. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367(9526):1903-12.
  • De Denus S, Sanoski CA, Carlsson J, Opolski G, Spinler SA. Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis. Arch Intern Med. 2005;165:258-64.
  • Ezekowitz MD, Wallentin L, Connolly SJ, Parekh A, Chernick MR, Pogue J, et al; RE-LY Steering Committee and Investigators. Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. Circulation. 2010 Nov 30;122(22):2246-53.
  • Freudenberger RS, Wilson AC, Kostis JB; AFFIRM Investigators and Committees. Comparison of rate versus rhythm control for atrial fibrillation in patients with left ventricular dysfunction (from the AFFIRM Study). Am J Cardiol. 2007 Jul 15;100(2):247-52.
  • Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al., ACC/AHA/ESC: Guía de práctica clínica 2006 para el manejo de pacientes con fibrilación auricular. (Versión resumida). Informe del Grupo de Trabajo para la elaboración de guías de práctica clínica del American College of Cardiology y de la American Heart Association y del Comité de Guías de Práctica Clínica de la Sociedad Europea de Cardiología. Rev Esp Cardiol. 2006;59(12):1329.e1-e64.
  • Gillis AM, Verma A, Talajic M, Nattel S, Dorian P; CCS Atrial Fibrillation Guidelines Committee. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management. Can J Cardiol. 2011 Jan-Feb;27(1):47-59.
  • Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al, ACTIVE W Investigators. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE. W Substudy. J Am Coll Cardiol. 2007;50(22):2156-61.
  • Imízocz Zubigaray MA, Erviti López J. ¿Cuál puede ser el papel de los nuevos anticoagulantes en la fibrilación auricular no valvular?. Boletín de Información Farmacoterapéutica de Navarra. 2011;19:29-43.
  • Lafuente-Lafuente C, Mahé I, Extramiana F. Management of atrial fibrillation. BMJ. 2009 Dec 23;339:b5216.
  • Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2007;(4):CD005049.
  • Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80.
  • Mant J, Hobbs R, Fletcher K, Roalfe A, Fitzmaurice D, Lip G, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007;370:493-503.
  • Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol. 2010 Sep 7;56(11):827-37.
  • Miller CS, Grandi SM, Shimony A, Filion KB, Eisenberg MJ. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012 (pendiente publicar).
  • Miralles R, Camí J, Gutiírrez J, Torné J, Garcés JM, Badenas JM. Diclofenac versus dipyrone in acute renal colic: a double-blind controlled trial. Eur J Clin Pharmacol. 1987;33:527-8.
  • National Institute for Health and Clinical Excellence (NICE). Atrial fibrillation. Quick reference guide (actualizada Jun 2006) [acceso el 20 Abril 2011]. Disponible en: http://www.nice.org.uk/nicemedia/pdf/CG036quickrefguide.pdf
  • Piccini JP, Hasselblad V, Peterson ED, Washam JB, Califf RM, Kong DF. Comparative efficacy of dronedarone and amiodarone for the maintenance of sinus rhythm in patients with atrial fibrillation. J Am Coll Cardiol. 2009 Sep 15;54(12):1089-95. Review. Erratum in: J Am Coll Cardiol. 2010 May 11;55(19):2185.
  • Ruiz-Ortiz M, Romo E, Mesa D, Delgado M, Anguita M, López-Granados A, y col. Predicción de eventos embólicos en pacientes con fibrilación auricular no valvular: evaluación del score CHADS2 en una población mediterránea. Rev Esp Cardiol. 2008;61:29-35.
  • Segal JB, McNamara RL, Miller MR, Powe NR, Goodman SN, Robinson KA, et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter. Cochrane Database Syst Rev. 2007 Jul 18;(3):CD001938.
  • Singh BN, Singh SN, Reda DJ, Tang XC, López B, Harris CL, et al, for the Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) Investigators. Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 2005;352(18):1861-72.
  • Van Gelder IC, Groenveld HF, Crijns HJGM, Tuininga YS, Tijssen JGP, Alings AM, et al. Lenient versus strict rate control in patients with atrial fibrillation. N Engl J Med. 2010;362:111-222.
  • Wallentin L, Yusuf S, Ezekowitz MD, Alings M, Flather M, Franzosi MG, et al; RE-LYinvestigators. Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. Lancet. 2010 Sep18;376(9745):975-83.
  • Wilber DJ, Pappone C, Neuzil P, De Paola A, Marchlinski F, Natale A, et al; ThermoCool AF Trial Investigators. Comparison of antiarrhythmic drug therapy and radiofrequency catheter ablation in patients with paroxysmal atrial fibrillation: a randomized controlled trial. JAMA. 2010 Jan27;303(4):333-40.

Flúter auricular

  • García-Cosío F, Pastor A, Núñez A, Magalhaes AP, Awamleh P. Flúter auricular: perspectiva clínica actual. Rev Esp Cardiol. 2006;59(8):816-31.
  • Sawhney NS, Anousheh R, Chen WC, Feld GK. Diagnosis and management of typical atrial flutter. Cardiol Clin. 2009 Feb;27(1):55-67, viii.

Hipertensión arterial esencial

  • Angiotensin-II receptor antagonists: what is the evidence for their place in therapy? MeReC Bulletin Volume 20, Number 2, January 2010.
  • Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. HYVET Study Group. Treatment of hypertension in patients 80 years of age or older. N Engl J Med. 2008;358(18):1887-98.
  • Benetos A, Rossignol P, Cherubini A, Joly L, Grodzicki T, Rajkumar C, et al. Polypharmacy in the Aging Patient: Management of Hypertension in Octogenarians. JAMA 2015 Jul 14;314(2):170-80.
  • Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials. BMJ. 2008;336:1121-3.
  • Blumenthal JA, Babyak MA, Hinderliter A, Watkins LL, Craighead L, Lin PH, et al. Effects of the DASH diet alone and in combination with exercise and weight loss on blood pressure and cardiovascular biomarkers in men and women with high blood pressure: the ENCORE study. Arch Intern Med. 2010 Jan 25;170(2):126-35.
  • Briasoulis A, Agarwal V, Tousoulis D, Stefanadis C. Effects of antihypertensive treatment in patients over 65 years of age: a meta-analysis of randomised controlled studies. Heart. 2014 Feb;100(4):317-23.
  • Chobanian AV. Isolated Systolic Hypertension in the Elderly. N Engl J Med. 2007;357:789-96.
  • Cushman WC, Davis BR, Pressel SL, Cutler JA, Einhorn PT, Ford CE, et al. Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. J Clin Hypertens (Greenwich). 2012;14:20–31.
  • Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, et al., ACCORD Study Group. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 Apr 29;362(17):1575-85.
  • Daskalopoulou SS, Rabi DM, Zarnke KB, Dasgupta K, Nerenberg K, Cloutier L, et al. The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. Can J Cardiol. 2015 May;31(5):549-68. doi: 10.1016/j.cjca.2015.02.016. PMID: 25936483. Disponible en: https://www.onlinecjc.ca/article/S0828-282X(15)00130-0/fulltext

  • Díaz A, García A, Hernández MJ, Montero MJ, Sierra AM. Sin duda, los IECA. El Ojo de Markov. 2014:27. Disponible en: https://www.saludcastillayleon.es/portalmedicamento/es/cim-sacyl/ojo-markov/duda-ieca
  • Dorsch MP, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared with hydrochlorothiazide: a retrospective cohort analysis. Hypertension. 2011;57:689–94.
  • Duprez DA. Systolic hypertension in the elderly: addressing an unmet need. Am J Med. 2008;121(3):179-84.
  • Edwards C, Hundemer GL, Petrcich W, Canney M, Knoll G, Burns K et al. Comparison of Clinical Outcomes and Safety Associated With Chlorthalidone vs Hydrochlorothiazide in Older Adults With Varying Levels of Kidney Function. JAMA Netw Open. 2021 Sep 1;4(9):e2123365. doi: 10.1001/jamanetworkopen.2021.23365. PMID: 34524440.

  • Feldman RD, Zou GY, Vandervoort MK, Wong CJ, Nelson SA, Feagan BG. A simplified approach to the treatment of uncomplicated hypertension: a cluster randomized, controlled trial. Hypertension. 2009 Apr;53(4):646-53.
  • Gijón-Conde T, Gorostidi M, Camafort M, Abad-Cardiel M, Martín-Rioboof E , Morales-Olivas F,et al. Documento de la Sociedad Espanola de Hipertensión-Liga Espanola para la Lucha contra la Hipertensión Arterial (SEH-LELHA) sobre las guías ACC/AHA 2017 de hipertensión arterial. Hipertens Riesgo Vasc. 2018; 35(3): 119-129.
  • Hermida R, Ayala D, Mojón A, Fernández JR. Influence of circadian time of hypertension treatment on cardiovascular risk: results of the mapec study. Chronobiology International. 2010:8;1629-51.
  • James M Wright, Vijaya M Musini. Fármacos de primera línea para la hipertensión (Revision Cochrane traducida). En: Biblioteca Cochrane Plus 2009 Número 3. Oxford: Update Software Ltd. Disponible en: http://www.update-software.com. (Traducida de The Cochrane Library, 2009 Issue 3 Art no. CD001841. Chichester, UK: John Wiley & Sons, Ltd.).
  • James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb CH, Handler J, et al. 2014 Evidence-Based Guideline for the Managementof High Blood Pressure in Adults. Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). JAMA. doi:10.1001. Published online December 18, 2013.
  • Khan N, McAlister FA. Re-examining the efficacy of b-blockers for the treatment of hypertension: a meta-analysis. CMAJ. 2006;174(12):1737-42.
  • Hypertension Pathway. National Institute for Health and Care Excellece (NICE). Pathway last updated: 21 August 2015. [Acceso Octubre 2015]. Disponible en: http://pathways.nice.org.uk/pathways/hypertension
  • Manich A, Dalfó-Bacqué A. Crisis hipertensivas. AMF 2016;12(1):31-38.
  • Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, et al. SystTematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148(1):16-29.
  • Messerli FH, Bangalore S. Half a century of hydrochlorothiazide: facts, fads, fiction, and follies. Am J Med. 2011; 124: 896-9.
  • National Institute for Health and Clinical Excellence (NICE). Hypertension: management of hypertension in adults in primary care. Quick reference guide, Jun 2006 [acceso 19 Abril 2011]. [Traducción al español: Molina R, grupos HTA semFYC y SAMFyC]. Disponible en: http://www.infodoctor.org/rafabravo/GuiaNICE2006.pdf
  • Ong HT. β blockers in hypertension and cardiovascular disease. BMJ 2007;334:946-9.
  • Rotaeche R, Aguirrezabala JR, Balagué L, Gorroñogoitia A, Idarreta I, Mozo C, et al. Guía de práctica clínica sobre hipertensión arterial. Actualización 2007. Osakidetza. Servicio Vasco de Salud, Departamento de Sanidad del Gobierno Vasco. [Acceso el 19 Abr 2011]. Disponible en: http://www.guiasalud.es/GPC/GPC_4_HTA_2007_compl.pdf
  • Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events. Systematic review and network meta-analyses. Hypertension. 2012;59:1110-7.
  • Roush GC, Kaur R, Ernst ME. Diuretics: A review and update. Journal of Cardiovascular Pharmacology and Therapeutics 2014, Vol 19(1) 5-13.
  • Seely EW, Ecker J. Chronic hypertension in pregnancy. Circulation 2014; 129(11):1254-61.
  • Tadic M, Cuspidi C, Grassi G, Mancia G. COVID-19 and arterial hypertension: Hypothesis or evidence? J Clin Hypertens (Greenwich). 2020 Jul 6:10.1111/jch.13925. doi: 10.1111/jch.13925. Epub ahead of print.

  • Tratamiento farmacológico de la hipertensión arterial. INFAC. 2015;23(5). [Acceso Octubre 2015]. Disponible en: http://www.osakidetza.euskadi.eus/contenidos/informacion/cevime_infac/es_cevime/adjuntos/Infac_vol_23_n05_Hipertension_arterial.pdf
  • Unger T, Claudio Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D et al. 2020 International Society of Hypertension Global Hypertension Practice Guidelines. Hypertension. 2020;75:1334-57.

  • Vongpatanasin W. Resistant hypertension: a review of diagnosis and management. JAMA 2014 Jun 4;311(21):2216-24.
  • Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, et al; ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. J Am Coll Cardiol. 2010 Jun 29;56(1):77-85.
  • Weber M, Schiffrin E, White W, Mann S, Lindholm L, Kenerson J, et al. Clinical practice guidelines for the management of hypertension in the community. A statement by the American Society of Hypertension and the International Society o fHypertension. Journal of Hypertension. 2014;32:3–15.
  • Whelton PK, Carey RM, Aronow WS, Casey DE Jr,Collins KJ, Dennison Himmelfarb C, et al. 2017ACC/ AHA/ AAPA/ ABC/ ACPM/ AGS/ APhA/ ASH/ ASPC/ NMA/ PCNA guideline for the prevention, detection, evaluation, andmanagement of high blood pressure in adults: A report of theAmerican College of Cardiology/American Heart AssociationTask Force on Clinical Practice Guidelines. Hypertension. 2018;71:1269–1324 [epub Nov 13 , 2017].
  • Williams B, Mancia G, Spiering W, Enrico Rosei EA, Azizi M, Burnier M et al. Guia ESC/ESH 2018 sobre el diagnóstico y tratamiento de la hipertensión arterial. Grupo de Trabajo de la Sociedad Europea de Cardiologia (ESC) y la European Society of Hypertension (ESH) sobre el diagnóstico y tratamiento de la hipertension arterial Rev Esp Cardiol. 2019;72(2):160.e1-e78.
  • Wiysonge CS, Bradley H, Mayosi BM, Maroney R, Mbewu A, Opie LH, et al. Beta-blockers for hypertension. Cochrane Database Syst Rev. 2007 Jan 24;(1):CD002003.

Hipotensión ortostática

  • Plana Blanco A, Moreno Álvarez P. Pérdida breve de conciencia. AMF 2014;10(6):344-8.

Insuficiencia cardíaca crónica

  • Ahmed A, Gambassi G, Weaver MT, Young JB, Wehrmacher WH, Rich MW. Effects of discontinuation of digoxin versus continuation at low serum digoxin concentrations in chronic heart failure. Am J Cardiol. 2007;100(2):280-4.
  • Anguita M, Ojeda S. Tratamiento médico de la insuficiencia cardíaca por disfunción diastólica. Rev Esp Cardiol. 2006;6(Supl F):53F-58F.
  • Anker SD, Butler J, Filippatos G, Ferreira JP, Bocchi E, Böhm M, et al; EMPEROR-Preserved Trial Investigators. Empagliflozin in Heart Failure with a Preserved Ejection Fraction. N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMoa2107038. Epub ahead of print. PMID: 34449189.
  • Aurigemma GP, Gaasch WH. Diastolic Heart Failure. N Engl J Med. 2004;351:1097-105.
  • Castro A, Barge E. Concepto y pronóstico de insuficiencia cardíaca con fracción de eyección normal. Rev Esp Cardiol. 2006;6(Supl F):9F-14F.
  • Chronic heart failure in adults: diagnosis and management. NICE guideline [NG106] (2018). [Acceso 18/09/2021]. Disponible en: https://www.nice.org.uk/guidance/ng106
  • Cortés G, De Gisbert B. Insuficiencia Cardiaca. AMF 2021;17(6): 314-24.
  • De Groote P, Delour P, Mouquet F, Lamblin N, Dagorn J, Hennebert O, et al. The effects of beta-blockers in patients with stable chronic heart failure. Predictors of left ventricular ejection fraction improvement and impact on prognosis. Am Heart J. 2007 Sep;154(3):589-95.
  • Felker GM, Lee KL, Bull DA, Redfield MM, Stevenson LW, Goldsmith SR, et al., NHLBI Heart Failure Clinical Research Network. Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med. 2011 Mar 3;364(9):797-805.
  • Hamaguchi S, Kinugawa S, Tsuchihashi-Makaya M, Goto K, Goto D, Yokota T, et al. Spironolactone use at discharge was associated with improved survival in hospitalized patients with systolic heart failure. Am Heart J. 2010 Dec;160(6):1156-62.
  • Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, et al., writing on behalf of the 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult Writing Committee. 2009 Focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009;119:1977-2016.
  • Jiménez-Navarro MF, García-Pinilla JM, Montiel A, de Teresa E. Tratamiento médico de la insuficiencia cardíaca por disfunción sistólica. Rev Esp Cardiol. 2006;6(Supl F):46F-52F.
  • McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, et al; ESC Scientific Document Group. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021 Aug 27:ehab368. doi: 10.1093/eurheartj/ehab368. Epub ahead of print. PMID: 34447992.
  • Le Jemtel TH, Padeleti M, Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007;49(2):171-80.
  • López-Sendón J. Bases y evidencias clínicas de los efectos de los nuevos tratamientos farmacológicos en la insuficiencia cardíaca. Rev Esp Cardiol. 2004;57(5):447-64.
  • Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS. Guía ESC 2016 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) de diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica. Rev Esp Cardiol. 2016;69(12):1167.e1-e85.
  • Scottish Intercollegiate Guidelines Network. Management of chronic heart failure. Guideline No. 95; 2007 Feb. [acceso el 22 Abr 2011]. Disponible en: http://www.sign.ac.uk/pdf/sign95.pdf
  • Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients ≥ 65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol. 2008;101:217-22.
  • Solomon SD, McMurray JV, Anand IS, Ge J, Lam CSP, Maggioni AP, et for the PARAGON-HF investigators. Angiotensin–Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction. N Engl J Med 2019 [in press] DOI: 10.1056/NEJMoa1908655.
  • Talajic M, Khairy P, Levesque S, Connolly SJ, Dorian P, Dubuc M, et al., AF-CHF Investigators. Maintenance of sinus rhythm and survival in patients with heart failure and atrial fibrillation. J Am Coll Cardiol. 2010 Apr 27;55(17):1796-802. Erratum in: J Am Coll Cardiol. 2010 Jun15;55(24):2788
  • Tribouilloy C, Rusinaru D, Leborgne L, Peltier M, Massy Z, Slama M. Prognostic impact of angiotensin-converting enzyme inhibitor therapy in diastolic heart failure. Am J Cardiol. 2008;101:639-44.
  • Urrutia A, Lupón J, Altemir S, González B, Herreros J, Díez C. Uso de bloqueadores beta en pacientes ancianos con insuficiencia cardíaca. Med Clin (Barc). 2006;126(6):206-10.
  • Verdú JM, Pacheco V, Amado E, Esgueva N, López N, Alemany L, et al. Insuficiència cardíaca. Guies de pràctica clínica (2007). Institut Catalá de la Salut. Departament de Salut. Generalitat de Catalunya. [acceso 19 Abr 2011]. Disponible en: http://www.gencat.cat/ics/professionals/guies/docs/guia_insuficiencia_cardiaca.pdf
  • Verdú JM, Barroso A, Bernáldez MJ, Domíngueza M, Pie M, Sancho F, et al. Betabloqueantes en el tratamiento de la insuficiencia cardiaca estable en atención primaria. Rev Esp Cardiol. 2009; 62(10):1141-8
  • Yan A, Yan R, Liu P. Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials. Ann Intern Med. 2005;142(2):132-45.
  • Wiviott SD, Raz I, Bonaca MP, et al., on behalf of the DECLARE–TIMI 58 Investigators. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2018;Nov 10:[Epub ahead of print].
  • Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al; EMPA-REG OUTCOME Investigators. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015 Nov 26;373(22):2117-28. doi: 10.1056/NEJMoa1504720. Epub 2015 Sep 17. PMID: 26378978.

Insuficiencia venosa crónica

  • Informe de Posicionamiento Terapéutico de sulodexida (Aterina®, Dovida®) en insuficiencia venosa crónica, úlcera venosa crónica y claudicación intermitente IPT, 9/2019. V1 Agencia Española de Medicamentos y Productos Sanitarios Comité de Medicamentos de Sacyl.(2019). Disponible en: https://www.aemps.gob.es/medicamentosUsoHumano/informesPublicos/docs/IPT-sulodexida-Aterina-Dovida-IVC-CI.pdf

  • Management of chronic venous leg ulcers. A national clinical guideline (Año 2010). Guideline 120. Scottish Intercollegiate Guidelines Network (SIGN). [Acceso el 19 Abr 2011]. Disponible en: http://www.sign.ac.uk/pdf/sign120.pdf
  • Martínez-Zapata MJ, Moreno RM, Gich I, Urrútia G, Bonfill X, Chronic Venous Insufficiency Study Group. A randomized, double-blind multicentre clinical trial comparing the efficacy of calcium dobesilate with placebo in the treatment of chronic venous disease. Eur J Vasc Endovasc Surg. 2008;35(3):358-65.
  • Martínez-Zapata MJ, Vernooij RWM, Simancas-Racines D, Uriona Tuma SM, Stein AT, Moreno Carriles RMM, et al. Phlebotonics for venous insufficiency. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No.: CD003229. DOI: 10.1002/14651858.CD003229.pub4. [Acceso el 1 oct 2021]. Disponible en: https://www.cochranelibrary.com/es/cdsr/doi/10.1002/14651858.CD003229.pub4/full/es
  • Navas Hergueta ML, López Laguna AN. Insuficiencia venosa crónica. AMF. 2011; 7 (9):509-14.
  • Raju S, Neglén P. Chronic Venous Insufficiency and Varicose Veins. N Engl J Med. 2009; 360:2319-27.
  • Sharif MA, Soong CV, Lau LL, Corvan R, Lee B, Hannon RJ. Endovenous laser treatment for long saphenous vein incompetence. Br J Surg. 2006;93(7):831-5.

Profilaxis de la endocarditis

  • Habib G, Lancellotti P, Antunes MJ, Bongiorni MG, Casalta JP, Del Zotti F et al. Guía ESC 2015 sobre el tratamiento de la endocarditis infecciosa. Rev Esp Cardiol. 2016; 69(1):69.e1-e49.
  • Nishimura RA, Carabello BA, Faxon DP, Freed MD, Lytle BW, O'Gara PT, et al. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2008;118:887-96.
  • Prophylaxis against infective endocarditis. Antimicrobial prophylaxis against infective endocarditis in adults and children undergoing interventional procedures. NICE. Clinical guideline 64 (2008). [Acceso el 20 Abr 2011]. Disponible en: http://guidance.nice.org.uk/nicemedia/live/11938/40039/40039.pdf